Polymorphism in the peroxisome proliferator-activated receptor α gene influences the risk for Alzheimer's disease

被引:47
作者
Brune, S
Kölsch, H
Ptok, U
Majores, M
Schulz, A
Schlosser, R
Rao, ML
Maier, W
Heun, R
机构
[1] Univ Bonn, Dept Psychiat, D-53105 Bonn, Germany
[2] Johannes Gutenberg Univ Mainz, Dept Psychiat, D-6500 Mainz, Germany
关键词
Alzheimer's disease; PPAR-alpha; insulin; association; amyloid-beta; APOLIPOPROTEIN-E; CEREBROSPINAL-FLUID; FATTY-ACIDS; EXPRESSION; METABOLISM; CORONARY; DEMENTIA; PPAR; ATHEROSCLEROSIS; LIPOPROTEIN;
D O I
10.1007/s00702-003-0018-6
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The peroxisome proliferator-activated receptor alpha (PPAR-alpha) is a member of the steroid hormone super family of ligand-inducible transcription factors, involved in glucose and lipid metabolism. We screened for polymorphisms in the PPAR-alpha gene and detected two known polymorphisms located in exon 5 and intron 7. These polymorphisms were investigated for their possible association with Alzheimer's disease (AD) and for their effect in carriers of an insulin gene (INS) polymorphism. The PPAR-alpha C --> G polymorphism in exon 5 (L162V) was associated with AD, in that the V-allele was more frequent in AD patients than in healthy subjects. Further data analysis revealed that carriers of an PPAR-alpha L162V V-allele and an INS-1 allele presented with an increased risk for AD. Cerebrospinal fluid amyloid-beta levels were influenced by PPAR-alpha L162V genotype. These results suggest, that PPAR-alpha polymorphism may be a risk factor for AD.
引用
收藏
页码:1041 / 1050
页数:10
相关论文
共 34 条
  • [1] Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
    Andreasen, N
    Minthon, L
    Davidsson, P
    Vanmechelen, E
    Vanderstichele, H
    Winblad, B
    Blennow, K
    [J]. ARCHIVES OF NEUROLOGY, 2001, 58 (03) : 373 - 379
  • [2] Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans - No alteration in adipose tissue of obese and NIDDM patients
    Auboeuf, D
    Rieusset, J
    Fajas, L
    Vallier, P
    Frering, V
    Riou, JP
    Staels, P
    Auwerx, J
    Laville, M
    Vidal, H
    [J]. DIABETES, 1997, 46 (08) : 1319 - 1327
  • [3] NEURONAL LOSS, NEUROFIBRILLARY TANGLES AND GRANULOVACUOLAR DEGENERATION IN HIPPOCAMPUS WITH AGING AND DEMENTIA - QUANTITATIVE STUDY
    BALL, MJ
    [J]. ACTA NEUROPATHOLOGICA, 1977, 37 (02) : 111 - 118
  • [4] CSF total tau, aβ42 and phosphorylated tau protein as biomarkers for Alzheimer's disease
    Blennow, K
    Vanmechelen, E
    Hampel, H
    [J]. MOLECULAR NEUROBIOLOGY, 2001, 24 (1-3) : 87 - 97
  • [5] Memory improvement following induced hyperinsulinemia in Alzheimer's disease
    Craft, S
    Newcomer, J
    Kanne, S
    DagogoJack, S
    Cryer, P
    Sheline, Y
    Luby, J
    DagogoJack, A
    Alderson, A
    [J]. NEUROBIOLOGY OF AGING, 1996, 17 (01) : 123 - 130
  • [6] CRAFT S, 1993, BEHAV NEUROSCI, V107, P926
  • [7] Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease - Relationship to severity of dementia and apolipoprotein E genotype
    Craft, S
    Peskind, E
    Schwartz, MW
    Schellenberg, GD
    Raskind, M
    Porte, D
    [J]. NEUROLOGY, 1998, 50 (01) : 164 - 168
  • [8] The peroxisome proliferator-activated receptor α-selective activator ciprofibrate upregulates expression of genes encoding fatty acid oxidation and ketogenesis enzymes in rat brain
    Cullingford, TE
    Dolphin, CT
    Sato, H
    [J]. NEUROPHARMACOLOGY, 2002, 42 (05) : 724 - 730
  • [9] Peroxisome proliferator-activated receptors: Nuclear control of metabolism
    Desvergne, B
    Wahli, W
    [J]. ENDOCRINE REVIEWS, 1999, 20 (05) : 649 - 688
  • [10] CONTROL OF THE PEROXISOMAL BETA-OXIDATION PATHWAY BY A NOVEL FAMILY OF NUCLEAR HORMONE RECEPTORS
    DREYER, C
    KREY, G
    KELLER, H
    GIVEL, F
    HELFTENBEIN, G
    WAHLI, W
    [J]. CELL, 1992, 68 (05) : 879 - 887